Literature DB >> 35224016

Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? "The Pro Position".

Neil O'Moráin1, Jayne Doherty1, Roisin Stack1, Glen A Doherty1.   

Abstract

BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disorder affecting the gastrointestinal tract with disease behaviour based on the depth and severity of mucosal injury. Cumulative injury can result in complications including stricture formation and penetrating complications which often require surgical resection of diseased segments of the intestine resulting in significant morbidity. Accurate assessment of disease activity and appropriate treatment is essential in preventing complications.
SUMMARY: Treatment targets in the management of CD have evolved with the advent of more potent immunosuppressive therapy. Targeting the resolution of sub-clinical inflammation and achieving mucosal healing is associated with the prevention of stricturing and penetrating complications. Identifying non-invasive modalities to assess mucosal healing remains a challenge. KEY MESSAGES: Mucosal healing minimizes the risk of developing disease complications, prolongs steroid-free survival, and reduces hospitalization and the need for surgical intervention.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Clinical remission; Crohn's disease; Disease assessment; Mucosal healing; Treatment targets

Year:  2021        PMID: 35224016      PMCID: PMC8820165          DOI: 10.1159/000519521

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  38 in total

1.  Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.

Authors:  J-F Colombel; W Reinisch; G J Mantzaris; A Kornbluth; P Rutgeerts; K L Tang; A Oortwijn; G S Bevelander; F J Cornillie; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2015-03-01       Impact factor: 8.171

Review 2.  Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Authors:  Paul Rutgeerts; Severine Vermeire; Gert Van Assche
Journal:  Gut       Date:  2007-04       Impact factor: 23.059

3.  Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.

Authors:  Gilles Boschetti; Patrick Garnero; Driffa Moussata; Charlotte Cuerq; Corinne Préaudat; Remi Duclaux-Loras; Anne Mialon; Jocelyne Drai; Bernard Flourié; Stephane Nancey
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

4.  Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease.

Authors:  Clara Yzet; Momar Diouf; Jean-Philippe Le Mouel; Franck Brazier; Justine Turpin; Julien Loreau; Jean Louis Dupas; Laurent Peyrin-Biroulet; Mathurin Fumery
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-16       Impact factor: 11.382

Review 5.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Mahmoud H Mosli; Guangyong Zou; Sushil K Garg; Sean G Feagan; John K MacDonald; Nilesh Chande; William J Sandborn; Brian G Feagan
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

Review 6.  Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?

Authors:  Christopher Ma; Robert Battat; Claire E Parker; Reena Khanna; Vipul Jairath; Brian Gordon Feagan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-01-03       Impact factor: 3.869

Review 7.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

Review 8.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization.

Authors:  Benjamin Click; Eric J Vargas; Alyce M Anderson; Siobhan Proksell; Ioannis E Koutroubakis; Claudia Ramos Rivers; Jana G Hashash; Miguel Regueiro; Andrew Watson; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

10.  Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.

Authors:  Sjoukje-Marije Haisma; Henkjan J Verkade; Rene Scheenstra; Hubert P J van der Doef; Frank A J A Bodewes; Patrick F van Rheenen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-10       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.